Compare
Innoviva vs Lilly (Eli) (INVA vs LLY)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Innoviva (INVA) returned +4.8% and Lilly (Eli) (LLY) +46.2%; so far this year the figures are -4.5% and +26.0%.
Lilly (Eli) is the larger company by market value, about 936.6 times the size of Innoviva.
On trailing earnings, INVA trades at 9.6 times and LLY at 43.9 times.
Revenue grew +12.8% at INVA and +45.5% at LLY over the last year.
INVA pays no dividend. LLY yields 0.49%.
Data as of the latest close. Not investment advice.
Relative performance
| INVA | LLY | |
|---|---|---|
| Price | $19.10 | $1,354.00 |
| 1-day | -0.73% | -0.79% |
| YTD | -4.45% | +25.99% |
| 1 year | +4.77% | +46.25% |
| 3 years | +53.78% | +144.20% |
| Market cap | $1.4B | $1.27T |
| P/E | 9.6 | 43.9 |
| P/S | 3.10 | 14.73 |
| P/B | 1.19 | 31.63 |
| Revenue growth | +12.80% | +45.50% |
| EPS growth | +40.80% | +50.70% |
| Gross margin % | 74.5 | 83.6 |
| Net margin % | 44.1 | 31.9 |
| ROE % | 17.0 | 68.5 |
| Debt / equity | 0.23 | 1.23 |
| FCF yield % | 13.4 | 2.4 |
| Dividend yield % | — | 0.49 |
| Beta | 0.28 | 0.29 |
| RSI (14) | 31.2 | 61.1 |
| Technical rating |